A COMPARISON OF ZIDOVUDINE, DIDANOSINE, ZALCITABINE AND NO ANTIRETROVIRAL THERAPY IN PATIENTS WITH ADVANCED HIV DISEASE

被引：9

作者：

TORRES, RA

BARR, MR

MCINTYRE, KI

THORNTON, JR

SHAY, WM

FELDMAN, RD

GEORGE, NJ

BRITTON, DJ

机构：

[1] St Vincent's Hospital, Medical Center of New York

[2] AIDS Institute, New York State Department of Health, New York, NY

来源：

INTERNATIONAL JOURNAL OF STD & AIDS | 1995年 / 6卷 / 01期

关键词：

HIV; ANTIRETROVIRAL; ZIDOVUDINE; DIDANOSINE; ZALCITABINE;

D O I：

10.1177/095646249500600105

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Three nucleoside analogues, zidovudine (AZT), didanosine (ddI), and zalcitabine (ddC), are approved for use in the treatment of patients with HIV infection. This retrospective study compares the 3 drugs and examines the overall utility of antiretroviral therapy by way of comparisons to a no treatment (No Rx) group in patients with advanced HIV disease. Patients with advanced HIV disease were enrolled in didanosine (August 1989-December 1990) or zalcitabine (October 1990-February 1992) expanded access programmes; continued on zidovudine treatment despite fulfilling criteria for zidovudine failure or intolerance; or maintained on no antiretroviral treatment. Statistical analysis revealed that patients on nucleoside analogue therapy had fewer opportunistic infections (P=0.001) than those who received no antiretroviral treatment. The Kaplan-Meier 12-month estimate of survival was significantly longer among patients who switched from zidovudine to zalcitabine but not among patients who switched to didanosine, when compared to the other 2 groups (P=0.05).

引用

页码：19 / 26

页数：8

共 20 条

[11]

340 Kingsland Street, Nutley, New Jersey 07110–1199. HIVID package insert

[12]

Lipsky J.L., Zalcitabine and didanosine, Lancet, 341, pp. 30-32, (1993)

[13]

Revision of the CDC surveillance case definition for acquired immune deficiency syndrome, MMWR, 36, pp. 15-15S, (1987)

[14]

Fischi M., Richman D.D., Grieco M.H., Et al., The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: A double-blind placebo-controlled trial, N Engl J Med, 317, pp. 185-191, (1987)

[15]

Fischi M.A., Richman D.D., Causey D.M., Et al., Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex, JAMA, 262, pp. 2405-2410, (1990)

[16]

Yarchoan R., Pluda J.M., Thomas R.V., Et al., Long-term toxicity/activity profile of 2′,3′-dideoxyinosine in AIDS or AIDS-related complex, Lancet, 336, pp. 526-529, (1990)

[17]

Larder B.A., Kemp S.D., Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT), Science, 246, pp. 1155-1158, (1990)

[18]

d'Aquila R., Johnson V., Kuritzkes D., Et al., Ninth International Conference on AIDS, HIV-1 drug resistance and syncytium-inducing phenotype: Associations with disease progression among ACTG 116B/117 subjects (abstract PO-B26–2046), (1993)

[19]

Abrams D., Goldman A., Launer C., Et al., A Comparative Trial of Didanosine or Zalcitabine in Patients with Human Immunodeficiency Virus Infection, N Engl J Med, 330, pp. 657-662, (1994)

[20]

Darbyshire J.H., Aboulker J.P., Didanosine for zidovudine-intolerant patients with HIV disease, Lancet, 340, pp. 1346-1347, (1992)

← 1 2 →